1 min read
Add as a preferred source on GoogleCorvus Pharmaceuticals' R&D Spending Rises to $17.8 Million in Q3
Expenses were $8.5 million in the year-earlier quarter, Chief Financial Officer Leiv Lea said.
Leiv Lea, chief financial officer of Corvus Pharmaceuticals, said research and development expenses totaled $17.8 million in the third quarter of 2026. The company recorded $8.5 million in those expenses in the same quarter of 2025.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.